Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Pipeline Review, H2 2017

Published: Sep, 2017 | Pages: 77 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Pipeline Review, H2 2017

Summary

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) pipeline Target constitutes close to 22 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The latest report Estrogen Receptor - Pipeline Review, H2 2017, outlays comprehensive information on the Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Estrogen receptor alpha (ERA) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR1. It is involved in pathological processes including breast cancer, endometrial cancer, and osteoporosis. It decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displaces RELA/p65 and associated co-regulators from the promoter. It recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP.  The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 7, 3, 1, 6 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Women's Health, Central Nervous System, Dermatology and Metabolic Disorders which include indications Breast Cancer, Metastatic Breast Cancer, Endometriosis, Female Contraception, Vasomotor Symptoms of Menopause (Hot Flashes), Bipolar Disorder (Manic Depression), Ductal Carcinoma In Situ, Encephalopathy, Hormone Sensitive Breast Cancer, Metastatic Prostate Cancer, Multiple Sclerosis, Neurology, Osteoporosis, Ovarian Cancer, Prostate Cancer, Vaginal Atrophy (Atrophic Vaginitis) and Vulvar Atrophy. 

Furthermore, this report also reviews key players involved in Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1)
- The report reviews Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Overview 8
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Therapeutics Development 9
Products under Development by Stage of Development 9
Products under Development by Therapy Area 10
Products under Development by Indication 11
Products under Development by Companies 12
Products under Development by Universities/Institutes 15
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Therapeutics Assessment 17
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Companies Involved in Therapeutics Development 23
Arvinas Inc 23
AstraZeneca Plc 23
Atossa Genetics Inc 23
Chamaeleo Pharma NV 24
EndoCeutics Inc 24
Genentech Inc 25
H3 Biomedicine Inc 25
Mithra Pharmaceuticals SA 26
Novartis AG 26
Nuevolution AB 27
Shenogen Pharma Group Ltd 27
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Drug Profiles 28
(acolbifene hydrochloride + prasterone) - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
(drospirenone + estetrol) - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
acolbifene hydrochloride - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
acolbifene hydrochloride + GnRH Agonist + prasterone - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Endoxifen - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Estetrol - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
fosfestrol - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
fulvestrant - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
fulvestrant - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
GDC-0927 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
H-3B6545 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Loseasonique - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
NDC-1308 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Small Molecule to Antagonize Estrogen Receptor Alpha for Metastatic Breast Cancer - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecules to Antagonize ER Alpha for Breast Cancer - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Small Molecules to Antagonize ER-Alpha for Breast Cancer - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Small Molecules to Antagonize ER-Alpha for Oncology - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Small Molecules to Antagonize Estrogen Receptor Alpha for Breast Cancer - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
SNG-8023 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
SR-16234 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
sulfestrol - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
TTC-352 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
VP-128 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Dormant Products 64
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Discontinued Products 66
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Product Development Milestones 67
Featured News & Press Releases 67
Sep 05, 2017: H3 Biomedicine Announces First Patient Dosed with H3B-6545 in Phase 1 Study in Breast Cancer 67
Sep 01, 2017: NICE says benefits of breast cancer drug fulvestrant too uncertain to make it cost effective 67
Aug 28, 2017: Faslodex receives US FDA approval as monotherapy for expanded use in breast cancer 68
Aug 18, 2017: Mithra Announces First Subject Completes Estelle Phase III Study 69
Aug 09, 2017: Mithra Pharmaceuticals: Recruitment Completed in Estelle Population PK Substudy 69
Jul 26, 2017: Faslodex receives EU approval as first-line therapy for advanced breast cancer 70
Jul 25, 2017: Atossa Genetics Provides Update on Fulvestrant Microcatheter Phase 2 Study 71
Jul 06, 2017: Mithra Strengthens E4 Patent Position in Australian Market 71
Jun 26, 2017: Estelle Phase IIB Results on Well-Being and Body Weight Published in Leading Peer-Reviewed journal 72
Jun 23, 2017: Faslodex (fulvestrant) receives positive CHMP opinion for use in 1st-line hormone receptor-positive advanced breast cancer 72
Jun 21, 2017: Mithra Completes Recruitment For Additional Estelle Safety Study 73
Jun 09, 2017: Mithra Receives Orphan Drug Designation From EMA For E4 In Neonatal Encephalopathy 74
May 12, 2017: Mithra to Initiate PK Study for Estelle 74
May 09, 2017: Atossa Genetics Receives Approval from Institutional Review Board for Continuation of its Fulvestrant Microcatheter Phase 2 Study 75
Mar 09, 2017: H3 Biomedicine to Present on H3B-6545 at 2017 American Association of Cancer Research Annual Meeting 75
Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 76
Disclaimer 77

List of Tables

Number of Products under Development by Stage of Development, H2 2017 9
Number of Products under Development by Therapy Areas, H2 2017 10
Number of Products under Development by Indication, H2 2017 11
Number of Products under Development by Companies, H2 2017 12
Products under Development by Companies, H2 2017 13
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14
Number of Products under Investigation by Universities/Institutes, H2 2017 15
Products under Investigation by Universities/Institutes, H2 2017 16
Number of Products by Stage and Mechanism of Actions, H2 2017 18
Number of Products by Stage and Route of Administration, H2 2017 20
Number of Products by Stage and Molecule Type, H2 2017 22
Pipeline by Arvinas Inc, H2 2017 23
Pipeline by AstraZeneca Plc, H2 2017 23
Pipeline by Atossa Genetics Inc, H2 2017 24
Pipeline by Chamaeleo Pharma NV, H2 2017 24
Pipeline by EndoCeutics Inc, H2 2017 25
Pipeline by Genentech Inc, H2 2017 25
Pipeline by H3 Biomedicine Inc, H2 2017 25
Pipeline by Mithra Pharmaceuticals SA, H2 2017 26
Pipeline by Novartis AG, H2 2017 27
Pipeline by Nuevolution AB, H2 2017 27
Pipeline by Shenogen Pharma Group Ltd, H2 2017 27
Dormant Products, H2 2017 64
Dormant Products, H2 2017 (Contd..1), H2 2017 65
Discontinued Products, H2 2017 66